Fadi F suhagra . Hamdan, Ph.D., Julie Gauthier, Ph.D., Dan Spiegelman, M.Sc., Anne Noreau, M.Sc., Yan Yang, M.D.N., Sylvia Dobrzeniecka, M.Sc.Sc., Elizabeth Perreau-Linck, M.Sc., Lionel Carmant, M.D., Man D’Anjou, M.D.D., Anjene M. Addington, Ph.D., Judith L. Rapoport, M.D., Lynn E. Delisi, M.D., Marie-Odile Krebs, M.D., Ph.D., Faycal Mouaffak, M.D., Ridha Joober, M.D., Ph.D., Laurent Mottron, M.D., Ph.D., Pierre Drapeau, Ph.D., Claude Marineau, M.Sc., M.B.A., Ronald G.D., Jean Claude Lacaille, Ph.D., Guy A.
Here we report a planned interim analysis conducted when the young children were 3 years of age. Participants The institutional review boards at each center approved the scholarly study, and written informed consent was obtained from the women before enrollment. Pregnant women with epilepsy who were getting monotherapy with carbamazepine, lamotrigine, phenytoin, or valproate had been enrolled. Women taking other antiepileptic medicines were not included due to insufficient numbers of patients. Females receiving polytherapy weren’t included due to the association of polytherapy with poorer outcomes1 and the shortcoming of the study to assess multiple feasible combinations of drugs.